# Zopa Retreatment and Vector Shedding in Adults With RRP

> **NCT06538480** · PHASE4 · RECRUITING · sponsor: **Precigen, Inc** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent Respiratory Papillomatosis
- Papillomavirus Infection
- Papillomaviridae

## Interventions

- **DRUG:** Zopapogene imadenovec (Zopa)

## Key facts

- **NCT ID:** NCT06538480
- **Lead sponsor:** Precigen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2027-12-02
- **Final completion:** 2028-12-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538480, "Zopa Retreatment and Vector Shedding in Adults With RRP". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06538480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*